Milnacipran and selective serotonin reuptake inhibitors in major depression

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 4, 1996, Pages 41-46

  Lopez Ibor, J ^a   Guelfi, J D ^b   Pletan, Y ^c   Tournoux, A ^c   Prost, J F ^c  

^a Hôpital Paul Brousse ^*  (Spain)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antidepressant therapy; Fluoxetine; Fluvoxamine; Milnacipran; Selective serotonin and noradrenaline reuptake inhibitors (SNRI); Selective serotonin reuptake inhibitors (SSRI)

Indexed keywords

FLUOXETINE; FLUVOXAMINE; MILNACIPARN; MILNACIPRAN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANXIETY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; DYSURIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

EID: 0029801370     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199609004-00006     Document Type: Conference Paper

References (32)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
2. Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants J Psychopharmacol 8:238-249.
3. Ansseau M, Papart P, Troisfontaines B (1994) Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 114:131-137.
4. Artigas F (1995) Selective serotonin/noradrenaline reuptake inhibitors (SNRIs): pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs 4:79-89.
5. Assié MB, Charveron M, Palmier C, Puozzo C, Moret C, Briley M (1992) Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 31:149-155.
6. Benfield P, Heel RC, Lewis SP (1986) Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:481-508.
7. Briley M, Moret C (1996) The role of noradrenaline in depression and its therapy: a reappraisal of its importance. Neurochemistry (in press).
8. Briley M, Prost JF, Moret C (1996) Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11 (suppl 4):9-14.
9. Clerc GE, Ruimy P, Verdeau-Paillès J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 9:139-143.
10. Covi L, Lipman R, McNair DM, Czerlinski T (1979) Symptomatic volunteers in multicenter drug trials. Prog Neuropsychopharmacol 3:521-533.
11. Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicentre study. Psychopharmacology 90: 131-138.
12. Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicentre study. J Affective Disord 18:289-299.
13. DeVane CL (1994) Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 97 (suppl 6A): 13S-23S.
14. Finley PR (1994) Selective serotonin reuptake inhibitors: pharmacological profiles and potential therapeutic distinctions. Ann Pharmacother 28:1359-1369.
15. Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 (suppl 4):35-39.
16. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 12:56-62.
17. Langer SZ, Schoemaker H (1988) Effects of antidepressants on monoamine transporters. Prog Neuropsychopharmacol Biol Psychiatry 12:193-216.
18. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V (1996) Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 11 (suppl 4):29-33.
19. Leonard BE (1989) The amine hypothesis of depression: a reassessment. In Topics in Neurochemistry and Neuropharmacology. vol 3, Biochemical and Pharmacological Aspects of Depression. Edited by Tipton KF, Youdim MBH. London: Taylor and Francis; pp 24-49.
20. Leonard BE (1996) Tricyclic antidepressants: effective, cheap but are they safe? J Psychopharmacol 10:35-38.
21. Macher JP, Sichel JP, Serre C, von Frenckell R, Huck JC, Demarez JP (1989) Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77-82.
22. Montgomery A, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
23. Montgomery SA, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9 (suppl 4):33-40.
24. Moret C, Briley M (1990) Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol 180:351-356.
25. Moret C, Charveron M, Finberg JPM, Couziner JP, Briley M (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219.
26. Neliat G, Bodinier M-C, Panconi E, Briley M (1996) Lack of effect of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the β-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology (in press).
27. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48:303-307.
28. Preskorn SH (1994) Antidepressant drug selection: criteria and options. J Clin Psychiatry 55:6-22.
29. Puozzo C, Filaquier C, Briley M (1985) Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers. Br J Clin Pharmacol 20: 291P-292P.
30. Raskin A, Schulterbrandt J, Reatig N, Rice CE (1967) Factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressions. J Consult Psychol 31:270-278.
31. Serre C, Clerc G, Escande M (1986) An early clinical trial of midalcipran, 1 -phenyl-1 -diethyl-aminocarbony 1-2-amino-methyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant. Curr Ther Res 39:156-164.
32. Spitzer R, Endicott J, Robins E (1978) Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 34:773-778.